These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22348348)

  • 1. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.
    Komachi M; Sato K; Tobo M; Mogi C; Yamada T; Ohta H; Tomura H; Kimura T; Im DS; Yanagida K; Ishii S; Takeyoshi I; Okajima F
    Cancer Sci; 2012 Jun; 103(6):1099-104. PubMed ID: 22348348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
    Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
    Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
    Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
    J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.
    Boucharaba A; Serre CM; Guglielmi J; Bordet JC; Clézardin P; Peyruchaud O
    Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9643-8. PubMed ID: 16769891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.
    Sako A; Kitayama J; Shida D; Suzuki R; Sakai T; Ohta H; Nagawa H
    J Surg Res; 2006 Jan; 130(1):94-101. PubMed ID: 16171822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-WASP Control of LPAR1 Trafficking Establishes Response to Self-Generated LPA Gradients to Promote Pancreatic Cancer Cell Metastasis.
    Juin A; Spence HJ; Martin KJ; McGhee E; Neilson M; Cutiongco MFA; Gadegaard N; Mackay G; Fort L; Lilla S; Kalna G; Thomason P; Koh YWH; Norman JC; Insall RH; Machesky LM
    Dev Cell; 2019 Nov; 51(4):431-445.e7. PubMed ID: 31668663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
    Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
    Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
    David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
    PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer.
    Liao Y; Mu G; Zhang L; Zhou W; Zhang J; Yu H
    Dig Dis Sci; 2013 Dec; 58(12):3524-33. PubMed ID: 24061591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidic acid signaling via LPA
    Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
    Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.
    Xu X; Prestwich GD
    Cancer; 2010 Apr; 116(7):1739-50. PubMed ID: 20143443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor.
    Lou L; Chen YX; Jin L; Li X; Tao X; Zhu J; Chen X; Wu S; Ye W; He J; Ding G
    J Int Med Res; 2013 Feb; 41(1):55-63. PubMed ID: 23569130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of oncogenic K-ras on cell migration stimulated by lysophosphatidic acid receptor-2 in pancreatic cancer cells.
    Yoshikawa K; Tanabe E; Shibata A; Inoue S; Kitayoshi M; Okimoto S; Fukushima N; Tsujiuchi T
    Exp Cell Res; 2013 Feb; 319(3):105-12. PubMed ID: 23041208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model.
    Kamide D; Yamashita T; Araki K; Tomifuji M; Tanaka Y; Tanaka S; Shiozawa S; Shiotani A
    Cancer Sci; 2016 May; 107(5):666-73. PubMed ID: 26918517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    Yu X; Zhang Y; Chen H
    BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIF inhibitor, ISO-1, attenuates human pancreatic cancer cell proliferation, migration and invasion in vitro, and suppresses xenograft tumour growth in vivo.
    Cheng B; Wang Q; Song Y; Liu Y; Liu Y; Yang S; Li D; Zhang Y; Zhu C
    Sci Rep; 2020 Apr; 10(1):6741. PubMed ID: 32317702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
    So J; Wang FQ; Navari J; Schreher J; Fishman DA
    Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LPA receptor 2 mediates LPA-induced endometrial cancer invasion.
    Hope JM; Wang FQ; Whyte JS; Ariztia EV; Abdalla W; Long K; Fishman DA
    Gynecol Oncol; 2009 Jan; 112(1):215-23. PubMed ID: 19019417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through P38 MAPK pathway.
    Zhu B; Shi S; Ma YG; Fan F; Yao ZZ
    Hepatogastroenterology; 2012 May; 59(115):785-9. PubMed ID: 22020916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TM4SF1 Regulates Pancreatic Cancer Migration and Invasion In Vitro and In Vivo.
    Cao J; Yang JC; Ramachandran V; Arumugam T; Deng DF; Li ZS; Xu LM; Logsdon CD
    Cell Physiol Biochem; 2016; 39(2):740-50. PubMed ID: 27459514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.